RxDoctor Payments Data

David Silvers, MD

Neurology · Palm Beach Gardens, FLNPI 1891739488

Payments from drug & device makers

$22,513in general payments, 2019–2025

Across 885 payments — averaging $25.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amneal Pharmaceuticals LLC$3K
  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Neurocrine Biosciences, Inc.$955
  • Lilly USA, LLC$854
  • Harmony Biosciences LLC$848
  • plus $14K from 54 others

What the payments were for

  • Consulting fees$740%
  • Speaking & faculty fees$2,22610%
  • Food & beverage$19,99689%
  • Education$2171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amneal Pharmaceuticals LLC52$2,962
AbbVie(2 entities)92$1,817
Teva Pharmaceuticals USA, Inc.48$1,283
Neurocrine Biosciences, Inc.36$955
Lilly USA, LLC35$854
Harmony Biosciences LLC21$848
MDD US Operations, LLC41$815
Neurelis, Inc.34$813
Biogen34$795
UCB, Inc.26$760
Acorda Therapeutics, Inc29$691
Kyowa Kirin, Inc.39$687
Pfizer26$623
SK Life Science, Inc.21$622
Argenx US, Inc.16$486
Upsher-smith Laboratories LLC31$461
AstraZeneca16$450
Adamas Pharmaceuticals, Inc.21$434
Sunovion Pharmaceuticals Inc.19$417
Lundbeck LLC15$406
Tanabe Pharma America, Inc.15$387
Amgen14$357
Otsuka America Pharmaceutical, Inc.12$355
Johnson & Johnson(2 entities)11$352
Sanofi15$335
Novartis13$319
EMD Serono, Inc.14$285
Biohaven Pharmaceutical Holding Company Ltd.14$282
Jazz Pharmaceuticals Inc.11$224
Arbor Pharmaceuticals, Inc.14$191
Bristol Myers Squibb9$173
Biohaven Pharmaceuticals, Inc.8$154
Merz Pharmaceuticals, LLC6$153
Bausch Health US, LLC8$146
Genentech USA, Inc.6$138
Acadia Pharmaceuticals Inc7$125
Axsome Therapeutics, Inc.4$117
Takeda Pharmaceuticals U.S.A., Inc.4$115
Boston Scientific4$93
E.r. Squibb & Sons, L.L.C.3$86
Cala Health, Inc.3$77
Almatica Pharma LLC3$75
C2n Diagnostics, LLC3$75
Idorsia Pharmaceuticals US Inc3$69
Avion Pharmaceuticals4$66
ANI Pharmaceuticals, Inc.2$66
Alnylam Pharmaceuticals Inc.3$56
Vanda Pharmaceuticals Inc.3$55
Catalyst Pharmaceuticals, Inc.2$50
Azurity Pharmaceuticals, Inc.2$49
Akcea Therapeutics, Inc.2$45
Inspire Medical Systems, Inc.1$40
Microtransponder, Inc.1$33
Insightec,inc1$27
Dynasplint Systems Inc.1$25
Abbott1$24
Eisai Inc.1$22
Averitas Pharma Inc.1$22
TMS Neurohealth Centers Inc.1$21
Ultragenyx Pharmaceutical Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,513 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$657,812
Medicare patients
1,287
Services billed
6,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FirdapseAmifampridine Phosphate16$1,452,942
EvrysdiRisdiplam14$367,298
GocovriAmantadine Hcl57$167,891
RytaryCarbidopa/Levodopa83$118,611
XcopriCenobamate20$58,388
Nurtec OdtRimegepant Sulfate30$54,301
Rivastigmine185$41,721
KeppraLevetiracetam15$40,938
Aimovig AutoinjectorErenumab-Aooe30$37,679
Droxidopa31$23,212
TrileptalOxcarbazepine13$20,026
NeuproRotigotine11$15,154
NamzaricMemantine Hcl/Donepezil Hcl13$14,069
Carbidopa-LevodopaCarbidopa/Levodopa440$13,048
Lacosamide52$10,646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Catalyst Pharmaceuticals, Inc.Firdapse$50$1,452,94216 claims
Genentech USA, Inc.Evrysdi$138$367,29814 claims
MDD US Operations, LLCGocovri$815$167,89157 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$2,962$120,467102 claims
SK Life Science, Inc.Xcopri$622$58,38820 claims
PfizerNurtec Odt$623$54,30130 claims
UCB, Inc.Neupro$760$15,15411 claims
AbbVieNamzaric$1,817$14,06913 claims
Almatica Pharma LLCSertraline Hcl$75$1,348115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Palm Beach Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →